X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare ASTRAZENECA PHARMA with Abbott India - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ASTRAZENECA PHARMA vs ABBOTT INDIA - Comparison Results

ASTRAZENECA PHARMA     Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

ABBOTT INDIA 
   Change

Formerly known as Knoll Pharmaceuticals Limited, Abbott India Limited (AIL) is a subsidiary of Abbott Capital India Limited in which the latter holds about 69% stake. It is involved in the discovery, development, manufacture and marketing of pharmace... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ASTRAZENECA PHARMA ABBOTT INDIA ASTRAZENECA PHARMA/
ABBOTT INDIA
 
P/E (TTM) x 92.1 41.1 224.3% View Chart
P/BV x 20.3 10.9 185.9% View Chart
Dividend Yield % 0.0 0.6 -  

Financials

 ASTRAZENECA PHARMA   ABBOTT INDIA
EQUITY SHARE DATA
    ASTRAZENECA PHARMA
Mar-18
ABBOTT INDIA
Mar-18
ASTRAZENECA PHARMA/
ABBOTT INDIA
5-Yr Chart
Click to enlarge
High Rs1,2786,110 20.9%   
Low Rs8833,996 22.1%   
Sales per share (Unadj.) Rs228.41,552.2 14.7%  
Earnings per share (Unadj.) Rs10.4188.8 5.5%  
Cash flow per share (Unadj.) Rs16.3196.4 8.3%  
Dividends per share (Unadj.) Rs055.00 0.0%  
Dividend yield (eoy) %01.1 0.0%  
Book value per share (Unadj.) Rs98.8796.6 12.4%  
Shares outstanding (eoy) m25.0021.25 117.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.73.3 145.3%   
Avg P/E ratio x104.226.8 389.5%  
P/CF ratio (eoy) x66.425.7 258.3%  
Price / Book Value ratio x10.96.3 172.4%  
Dividend payout %029.1 0.0%   
Avg Mkt Cap Rs m27,008107,376 25.2%   
No. of employees `0001.43.3 40.8%   
Total wages/salary Rs m1,5353,937 39.0%   
Avg. sales/employee Rs Th4,210.99,929.3 42.4%   
Avg. wages/employee Rs Th1,132.21,185.1 95.5%   
Avg. net profit/employee Rs Th191.11,207.7 15.8%   
INCOME DATA
Net Sales Rs m5,71032,985 17.3%  
Other income Rs m1231,170 10.5%   
Total revenues Rs m5,83334,155 17.1%   
Gross profit Rs m4635,245 8.8%  
Depreciation Rs m147162 91.0%   
Interest Rs m038 0.0%   
Profit before tax Rs m4386,215 7.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1792,203 8.1%   
Profit after tax Rs m2594,012 6.5%  
Gross profit margin %8.115.9 51.0%  
Effective tax rate %40.835.4 115.2%   
Net profit margin %4.512.2 37.3%  
BALANCE SHEET DATA
Current assets Rs m3,20922,655 14.2%   
Current liabilities Rs m2,0706,681 31.0%   
Net working cap to sales %20.048.4 41.2%  
Current ratio x1.63.4 45.7%  
Inventory Days Days7265 111.7%  
Debtors Days Days3529 119.8%  
Net fixed assets Rs m790835 94.6%   
Share capital Rs m50213 23.5%   
"Free" reserves Rs m2,41916,715 14.5%   
Net worth Rs m2,46916,928 14.6%   
Long term debt Rs m00-   
Total assets Rs m4,60524,162 19.1%  
Interest coverage xNM163.7-  
Debt to equity ratio x00-  
Sales to assets ratio x1.21.4 90.8%   
Return on assets %5.616.8 33.6%  
Return on equity %10.523.7 44.3%  
Return on capital %17.736.9 48.0%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m300369 81.3%   
Fx outflow Rs m2,0153,807 52.9%   
Net fx Rs m-1,715-3,438 49.9%   
CASH FLOW
From Operations Rs m881,527 5.8%  
From Investments Rs m-94-2,148 4.4%  
From Financial Activity Rs mNA-1,024 0.0%  
Net Cashflow Rs m-6-1,646 0.3%  

Share Holding

Indian Promoters % 0.0 0.0 -  
Foreign collaborators % 75.0 75.0 100.0%  
Indian inst/Mut Fund % 0.3 7.9 3.8%  
FIIs % 15.7 0.1 15,700.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 9.1 17.1 53.2%  
Shareholders   12,856 18,270 70.4%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ASTRAZENECA PHARMA With:   IPCA LABS  SANOFI INDIA  PANACEA BIOTECH  PROCTER & GAMBLE HEALTH  NOVARTIS  

Compare ASTRAZENECA PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices End on a Positive Note for Third Straight Day; Yes Bank Falls 5%(Closing)

Indian share markets traded on a positive note most of the day and ended marginally higher. Sectoral indices ended on a mixed note with stocks in the IT sector.

Related Views on News

PROCTER & GAMBLE HEALTH at All Time High; BSE HEALTHCARE Index Up 0.1% (Market Updates)

Jul 17, 2019 | Updated on Jul 17, 2019

PROCTER & GAMBLE HEALTH share price has hit an all time high at Rs 4,995 (up 4.4%). The BSE HEALTHCARE Index is up by 0.1%. Among the top gainers in the BSE HEALTHCARE Index today are PROCTER & GAMBLE HEALTH (up 4.4%) and SANOFI INDIA . The top losers include THYROCARE TECHNOLOGIES (down 0.2%) and CIPLA (down 0.2%).

PROCTER & GAMBLE HEALTH at All Time High; BSE HEALTHCARE Index Down 0.4% (Market Updates)

Jul 17, 2019 | Updated on Jul 17, 2019

PROCTER & GAMBLE HEALTH share price has hit an all time high at Rs 4,774 (up 1.4%). The BSE HEALTHCARE Index is down by 0.4%. Among the top gainers in the BSE HEALTHCARE Index today are PROCTER & GAMBLE HEALTH (up 1.4%) and ABBOTT INDIA (up 0.9%). The top losers include FORTIS HEALTHCARE (down 0.1%) and CADILA HEALTHCARE (down 0.1%).

ABBOTT INDIA Announces Quarterly Results (4QFY19); Net Profit Up 13.1% (Quarterly Result Update)

May 28, 2019 | Updated on May 28, 2019

For the quarter ended March 2019, ABBOTT INDIA has posted a net profit of Rs 1 bn (up 13.1% YoY). Sales on the other hand came in at Rs 9 bn (up 15.0% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 204.9% (Quarterly Result Update)

May 27, 2019 | Updated on May 27, 2019

For the quarter ended March 2019, ASTRAZENECA PHARMA has posted a net profit of Rs 98 m (up 204.9% YoY). Sales on the other hand came in at Rs 2 bn (up 26.3% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

ASTRAZENECA PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Mar 29, 2019 | Updated on Mar 29, 2019

Here's an analysis of the annual report of ASTRAZENECA PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of ASTRAZENECA PHARMA. Also includes updates on the valuation of ASTRAZENECA PHARMA.

More Views on News

Most Popular

These 3 Smallcap Stocks are Set to Make the Most of Smallcap Rebound(Profit Hunter)

Jul 9, 2019

As the sense of normalcy returns to the markets, the rebound in the quality smallcaps could be huge.

2 Stocks from Super Investor Sanjay Bakshi's Portfolio You Can Bet On...(The 5 Minute Wrapup)

Jul 12, 2019

Despite the current fear prevailing in the markets, both these stocks have the potential to deliver in 4-5 years.

A One Stock Crorepati(Profit Hunter)

Jul 4, 2019

Do you wish you could become a crorepati in the stock market? Read on...

After Disappointing Budget, Here's a Document that Concerns Largecap and Smallcap Investors(The 5 Minute Wrapup)

Jul 8, 2019

A new 'definition' of the stock universe that triggered the smallcap sell-off is back with the latest list...

Union Budget 2019-2020: More Style Over Substance(The 5 Minute Wrapup)

Jul 5, 2019

Did the Union Budget announce measures to stimulate the economy and bolster corporate earnings growth?

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

ASTRAZENECA PHARMA SHARE PRICE


Jul 17, 2019 (Close)

TRACK ASTRAZENECA PHARMA

  • Track your investment in ASTRAZENECA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ASTRAZENECA PHARMA

ASTRAZENECA PHARMA - STERLING BIOTECH COMPARISON

COMPARE ASTRAZENECA PHARMA WITH

MARKET STATS